866-997-4948(US-Canada Toll Free)

Published on : Dec 13, 2017

ALBANY, New York, December 13, 2017: Hemophilia A and B Therapeutics in Asia-Pacific Markets to 2023 - Growth Driven by Increasing Treatment-Receiving Pool, Launch of Long-Acting Replacement Therapies and Non-factor Therapy is the latest report added in the vast database of reports of ResearchMoz.biz which talks about the overall market landscape of the Hemophilia A and B therapeutics in the Asia Pacific for the given forecast period that ends in 2023. The research report covers the Asia Pacific market for hemophilia A and B therapeutics in terms of the latest trends that are prevailing in the market, driving and impeding factors of the global market, and the opportunities that may arise in the global market during the course of the forecast period. 

The research report also offers an in-depth analysis of the present market dynamics and sheds light on the competitive landscape of the Asia Pacific market for hemophilia A and B therapeutics. The study report is the compilation of the information collected through extensive assessment of the market and the data gathered from the professionals in the industry. This 133 page long research report also offers vital information on the key market players that are currently plying their trade in the Asia Pacific market for hemophilia A and B therapeutics. The report also maps the overall growth prospects of the global market over the course of the given forecast period of 2017 to 2023. 

Hemophilia is a scarce disorder affecting over 400,000 people across the globe. Hemophilia A is almost four to six times more common than hemophilia B, and over half of the patients affected by hemophilia A have been found to have severe form of hemophilia. The mainstay of the treatment given for hemophilia alter the missing factor IX or factor VIII, created using recombinant methods or plasma derived methods. Some patients might develop inhibitors for factor IX or factor VIII treatment and may need a bypassing agent, such as factor VIIa, to solve the bleeds. 

Get SAMPLE REPORT PDF: https://www.researchmoz.us/enquiry.php?type=S&repid=1389105

Patients suffering from hemophilia A or hemophilia B usually need a lifelong treatment to control or avoid bleeding incidences, and they are thus, considered to be the strongest factors responsible for driving the overall growth of the market. The present marketed product landscape consists of replacement factor therapies, also including the new long acting recombinant products and the current recombinant therapies. The market pipeline shows a sturdy promise and highlights an inclining shift from the short acting recombinant factor IX or factor VIII to the long acting recombinant factor VIII, and from the replacement of factor therapies to therapies that do not involve any factors. 

The Asia Pacific market for hemophilia A and hemophilia B is expected to reach a valuation of US$1.499 Bn in 2023 growing with a strong CAGR of 8.6%

Nonetheless, considerable unmet requirements still remain for the products that can inhibit the development of the inhibitors. Even though the pipeline in the later stage for the treatment of hemophilia seems to be promising, the overall market for the therapeutics of hemophilia A and hemophilia B, there are some factors that might impact negatively on the overall growth of the market over the coming years of the forecast period. One of the key restraining factors for the market is expected to be the low key penetration of the new therapies based on the long acting recombinant factors. These new therapies are still finding their feet in the most promising regional segments of the Asia Pacific market for hemophilia A and hemophilia B therapeutics such as India and China. A reason behind this low key penetration in these highly promising areas is expected to be the high cost required for the treatment. 

To order report Call USA – Canada Toll Free: 866-997-4948 or send an email on sales@researchmoz.us